A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2018
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2010 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 07 Sep 2007 Status changed from initiated to recruiting.